- Home
- AEYE vs PROK Comparison
AEYE vs PROK Comparison
Compare AEYE & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEYE
- PROK
- Stock Information
- Founded
- AEYE 2005
- PROK 2015
- Country
- AEYE United States
- PROK United States
- Employees
- AEYE N/A
- PROK N/A
- Industry
- AEYE Computer Software: Prepackaged Software
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEYE Technology
- PROK Health Care
- Exchange
- AEYE Nasdaq
- PROK Nasdaq
- Market Cap
- AEYE 153.6M
- PROK 126.8M
- IPO Year
- AEYE N/A
- PROK N/A
- Fundamental
- Price
- AEYE $11.30
- PROK $0.79
- Analyst Decision
- AEYE Strong Buy
- PROK Buy
- Analyst Count
- AEYE 5
- PROK 4
- Target Price
- AEYE $26.10
- PROK $5.00
- AVG Volume (30 Days)
- AEYE 141.0K
- PROK 1.1M
- Earning Date
- AEYE 04-29-2025
- PROK 05-09-2025
- Dividend Yield
- AEYE N/A
- PROK N/A
- EPS Growth
- AEYE N/A
- PROK N/A
- EPS
- AEYE N/A
- PROK N/A
- Revenue
- AEYE $35,201,000.00
- PROK $76,000.00
- Revenue This Year
- AEYE $20.29
- PROK N/A
- Revenue Next Year
- AEYE $18.65
- PROK N/A
- P/E Ratio
- AEYE N/A
- PROK N/A
- Revenue Growth
- AEYE 12.41
- PROK N/A
- 52 Week Low
- AEYE $8.91
- PROK $0.46
- 52 Week High
- AEYE $34.85
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- AEYE 46.68
- PROK 45.47
- Support Level
- AEYE $8.91
- PROK $0.65
- Resistance Level
- AEYE $11.96
- PROK $1.18
- Average True Range (ATR)
- AEYE 1.00
- PROK 0.17
- MACD
- AEYE 0.21
- PROK 0.03
- Stochastic Oscillator
- AEYE 78.36
- PROK 45.97
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's, and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.